Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Biliary tract cancer is one of the most aggressive and chemotherapy-refractory tumors. Although only curative treatment modality is surgery, most patients are not suitable for surgery due to advanced stage of the disease at diagnosis. Thus most patients with biliary tract cancer are possible candidates for palliative chemotherapy. The standard chemotherapeutic regimen is still to be defined, however. We performed a phase II study of combination chemotherapy with capecitabine and cisplatin in these patients to evaluate efficacy and toxicity of the regimen.

Methods

Patients with previously untreated metastatic, recurrent, or inoperable biliary tract cancer were enrolled. Eligible patients were screened as following: (1) histologically confirmed, (2) age between 18 and 75 years, (3) at least one measurable lesion according to RECIST criteria, (4) ECOG performance status ≤2, (5) a life expectancy of at least 3 months, and (6) adequate laboratory values. Patients received capecitabine (2,500 mg/m2/day, days 1 to 14) and cisplatin (60 mg/m2, day 1) every 3 weeks. Response was assessed for every two cycles of chemotherapy and treatment was stopped when tumor had progressed or stable with no further response.

Results

Thirty-two patients were enrolled, 20 (62.5%) were male and 12 (37.5%) were female and the median age was 54 years (33–71 years). Fifteen patients (46.9%) had gallbladder cancer, 13 (40.6%) had intrahepatic cholangiocarcinoma, and 4 (12.5%) had extrahepatic biliary cancer. The most frequent metastatic sites were lymph nodes (20/32, 62.5%) and liver (28/32, 56.3%). No complete response was observed and partial response was observed in 13/32 patients. By the intent-to-treat analysis, the overall response rate was 40.6% (95% CI, 23.7–59.4) with 0 CR and 13 PRs. Stable disease was observed in 3 patients (9.4%), and 11 patients (34.4%) had progressive disease. The median time to progression was 3.5 months (95% CI, 1.3–5.8), and the median overall survival was 12.4 months (95% CI, 6.3–18.5) after the median follow-up duration of 9.5 months (4.8–26.1 months). A total of 108 cycles of chemotherapy was delivered. Grade 3 hematologic toxicities included neutropenia (5, 15.6%), anemia (1, 3.1%), and thrombocytopenia (1, 3.1%) per patient, and no grade 4 hematologic toxicities were observed. Grade 3 non-hematologic toxicities included hyperbilirubinemia (2, 6.3%), increase of alkaline phosphatase (2, 6.3%), hand–foot syndrome (2, 6.3%), anorexia, and diarrhea (1, 3.1%) per patient, respectively. There was no treatment-related death.

Conclusion

The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin 53:5–26

    Article  PubMed  Google Scholar 

  2. Patel T (2002) Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10

    Article  PubMed  Google Scholar 

  3. Faivre J, Forman D, Esteve J, Obradovic M, Sant M (1998) Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group. Eur J Cancer 34:2184–2190

    Article  PubMed  CAS  Google Scholar 

  4. Shin HRJK, Won YJ, Park JG, 139 KCCR-affiliated Hospitals (2004) 2002 annual report of the Korea Central Cancer Registry. Cancer Res Treat 36:103–114

    Article  PubMed  Google Scholar 

  5. Hirono S, Tani M, Kawai M, Ina S, Uchiyama K, Yamaue H (2006) Indication of hepatopancreatoduodenectomy for biliary tract cancer (discussion 574–565). World J Surg 30:567–573

    Article  PubMed  Google Scholar 

  6. Jarnagin WR (2000) Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 19:156–176

    Article  PubMed  CAS  Google Scholar 

  7. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B (1995) Surgical treatment of cholangiocellular carcinoma. World J Surg 19:83–88

    Article  PubMed  CAS  Google Scholar 

  8. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111–118

    Article  PubMed  CAS  Google Scholar 

  9. Colleoni M, Di Bartolomeo M, Di Leo A, Zilembo N, Carnaghi C, Pandolfi A, Rimassa L, Artale S, Bajetta E (1995) Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur J Cancer 31A:2426–2427

    Article  PubMed  CAS  Google Scholar 

  10. Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E (2000) Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. Ann Oncol 11:762–763

    Article  PubMed  CAS  Google Scholar 

  11. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

    Article  PubMed  CAS  Google Scholar 

  12. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II,Raijman I (2001) Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7:3375–3380

    PubMed  CAS  Google Scholar 

  13. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 9:653–656

    Article  PubMed  CAS  Google Scholar 

  14. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578–586

    Article  PubMed  CAS  Google Scholar 

  15. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566–575

    Article  PubMed  CAS  Google Scholar 

  16. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK (2005) Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 92:246–251

    PubMed  CAS  Google Scholar 

  17. Y. Kang WKK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Philco M, Suarez T, Santamaria J (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol (Meeting Abstracts) 24

  18. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

    Article  PubMed  CAS  Google Scholar 

  19. Anderson JR, Bernstein L,Pike MC (1982) Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 38:407–416

    Article  PubMed  CAS  Google Scholar 

  20. Ellis PA, Norman A, Hill A, O’Brien ME, Nicolson M, Hickish T,Cunningham D (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31A:1594–1598

    Article  PubMed  CAS  Google Scholar 

  21. De Besi P, Sileni VC, Salvagno L, Tremolada C, Cartei G, Fosser V, Paccagnella A, Peracchia A,Fiorentino M (1986) Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 70:909–910

    PubMed  Google Scholar 

  22. Kang ea (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol (Meeting Abstracts) 24

  23. Weinerman B, Shah A, Fields A, Cripps IC, Wilson K, McCormick R, Temple W, Maroun J, Bogues W, Pater J et al (1992) Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 15:518–523

    Article  PubMed  CAS  Google Scholar 

  24. Walko CM,Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44

    Article  PubMed  CAS  Google Scholar 

  25. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung JB, Park MS, Yu JS, Yoon DS (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753–2758

    Article  PubMed  CAS  Google Scholar 

  26. Rich T (2002) Capecitabine and radiation therapy for advanced gastrointestinal malignancies. Oncology (Williston Park) 16:27–30

    Google Scholar 

  27. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14:1115–1120

    Article  PubMed  CAS  Google Scholar 

  28. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K (2006) A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339–1346

    Article  PubMed  CAS  Google Scholar 

  29. Murad AM, Guimaraes RC, Aragao BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, Moore FC (2003) Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 26:151–154

    Article  PubMed  CAS  Google Scholar 

  30. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183–186

    Article  PubMed  CAS  Google Scholar 

  31. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G,Papalambros E (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193–198

    Article  PubMed  CAS  Google Scholar 

  32. Thongprasert S, Napapan S, Charoentum C,Moonprakan S (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279–281

    Article  PubMed  CAS  Google Scholar 

  33. Cho JY, Nam JS, Park MS, Yu JS, Paik YH, Lee SJ, Lee DK,Yoon DS (2005b) A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei Med J 46:526–531

    CAS  Google Scholar 

  34. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F,Scheithauer W (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15:478–483

    Article  PubMed  CAS  Google Scholar 

  35. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H,Tsuyuguchi T (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647–653

    Article  PubMed  CAS  Google Scholar 

  36. Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB,Lee JH (2006) Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106:361–365

    Article  PubMed  CAS  Google Scholar 

  37. Ueno H, Okusaka T, Ikeda M, Takezako Y,Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91:1769–1774

    Article  PubMed  CAS  Google Scholar 

  38. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A,Louvet C (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339–1343

    Article  PubMed  CAS  Google Scholar 

  39. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N,Fulfaro F (2006) Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 17:vii68–vii72

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Kangnam-gu, Seoul, 135-710, South Korea

    Yong Sang Hong, Jeeyun Lee, Sang Cheol Lee, In Gyu Hwang, Joon Oh Park, Young Suk Park, Ho Yeong Lim & Won Ki Kang

  2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Seong-Ho Choi & Jin-Seok Heo

Authors
  1. Yong Sang Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeeyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Cheol Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. In Gyu Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seong-Ho Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin-Seok Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joon Oh Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Young Suk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ho Yeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Won Ki Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ho Yeong Lim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, Y.S., Lee, J., Lee, S.C. et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol 60, 321–328 (2007). https://doi.org/10.1007/s00280-006-0380-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0380-9

Keywords

Search

Navigation